Despite rising 8 percent in 2012, by most accounts it was a very disappointing year for Amarin (NASDAQ: AMRN) shareholders. After receiving FDA approval for Vascepa mid-year, and seeing its stock rise as much as 113%, shares came crashing down at the end ...
Even more importantly, this was an $8 and $9 stock the prior week. It seems hard to get excited here after such a big price drop this past week, but those calls were made that still implied high upside. On Thursday, Amarin Corp. PLC (NASDAQ: AMRN ...
Amarin Corp. plc (AMRN) announced that more than 90% of the targeted 1,612 ... CERS closed Tuesday's trading at $4.33, up 3.34%. In after-hours, the stock was up 30% to $5.64. Corindus Vascular Robotics Inc. (CVRS) rose more than 30% in extended trading ...
RTTNews · 5mon
On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Amarin (NASDAQ: AMRN) is a “speculative stock.” He added, “I think it's a don't-buy situation." He said that United Parcel Service (NYSE: UPS) is “going still higher. This is a ...
Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Amarin Corporation plc (NASDAQ:AMRN) and Anthera Pharmaceuticals ... exclusive access to our numerous stock reports and …
Amarin Corp. (NASDAQ: AMRN) started as Buy with $20 target at Citigroup ... Cardinal Financial Corp. (NASDAQ: CFNL) named as value stock of the day at Zacks. Crocs Inc. (NASDAQ: CROX) started as Buy with $17 target at Goldman …
DUBLIN (AP) _ Amarin Corp. PLC (AMRN) on Tuesday reported a loss of $27.5 million in its fourth quarter. On a per-share basis, the Dublin-based company said it had a loss of 10 cents. Losses, adjusted for pretax expenses and stock option expense ...
Citi upgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Buy with a price target of $2.50 (unchanged). Analyst Jonathan Eckard thinks the company is facing an uphill battle with the FDA, but in his view, the stock's current valuation doesn't reflect ...
The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga ... it’s not too surprising to see the stock moving higher,” Akiva Felt, an analyst ...
A year ago, they were trading at $3.12. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMRN at https://www.zacks.com/ap/AMRN
Yahoo! · 7mon